|Bid||1.1400 x 4000|
|Ask||1.1500 x 4000|
|Day's Range||1.0900 - 1.2200|
|52 Week Range||1.0000 - 3.9600|
|Beta (5Y Monthly)||0.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 01, 2022 - Aug 05, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.25|
Subscribe to Yahoo Finance Plus to view Fair Value for VSTM
The big shareholder groups in Verastem, Inc. ( NASDAQ:VSTM ) have power over the company. Institutions often own shares...
With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ: VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSOC) continue evaluation in both monotherapy and combination regimens. With incremental updates from ASCO, reiterated KOL enthusiasm, and more updates are upcoming in 2022 on a longer runway, RBC Capital continues to like the VSTM setup. The company plans to complete enrollment of all four trial cohor
BOSTON, June 06, 2022--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for people living with cancer, today announced an update from an interim analysis of its international Phase 2 RAMP 201 trial evaluating VS-6766 ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC), regardless of KRAS status.